Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has approved the conclusion of certain fundraising projects and the permanent allocation of surplus funds to supplement its working capital [1] Group 1: Fundraising Projects - The company has decided to conclude the fundraising projects related to the "Innovative Drug R&D and R&D Technology Center Building Purchase Project" specifically for the "Aibond® (Ainovelin Tablets) Phase III Clinical and Post-Marketing Research Project" and the "ACC008 Phase III/IV Clinical Project" [1] - The surplus funds from these projects amount to 28.3095 million yuan and 8.1898 million yuan, respectively, which will be used to permanently supplement the company's working capital [1]

Core Viewpoint - The company announced the conclusion of certain fundraising projects and the permanent allocation of surplus funds to working capital [1] Group 1: Project Conclusion - The company held its third board meeting on February 12, 2026, where it approved the conclusion of specific fundraising projects [1] - The projects concluded include the "Phase III clinical and post-marketing research project for Aibond® (Ainovelin tablets)" and the "Phase III/IV clinical project for ACC008" [1] - Both projects have reached the predetermined usable status as of the conclusion date [1] Group 2: Financial Details - As of December 31, 2025, the total surplus fundraising amount from the concluded projects is 36.4993 million yuan [1] - The company plans to permanently allocate the surplus funds to working capital [1] - Following the transfer of surplus funds, the company will cancel the corresponding fundraising special account [1]

Core Viewpoint - The company has approved the use of its own funds and bank acceptance bills to pay for fundraising projects, with plans to replace these with raised funds later, ensuring the normal implementation of fundraising projects [1][6][7] Summary of Fundraising Situation - The company raised a total of RMB 839.4 million by issuing 60 million shares at RMB 13.99 per share, with total issuance costs amounting to RMB 79.83 million [1][2] - The funds were fully received by July 13, 2020, and have been managed in a dedicated account as per regulatory requirements [1][2] Summary of Investment Projects - As of June 30, 2025, the raw material drug production R&D project has been completed, while other fundraising projects are ongoing [2][3] - Specific projects include the Phase III clinical project for Aibond (艾诺韦林片) and the ACC008 project, with total investments of RMB 53.22 million and RMB 38.60 million respectively [3][4] Reasons for Using Own Funds - The company has used its own funds and bank acceptance bills for several reasons, including the need to pay employee salaries and taxes, which cannot be paid directly from the fundraising account [4][5] - Additionally, payments for overseas equipment and services require foreign currency, which cannot be processed through the fundraising account [4][5] Operational Process for Fund Replacement - The company will regularly compile a detailed list of payments made with its own funds and bank acceptance bills, which will be approved by the financial department [5][6] - After approval, equivalent amounts will be transferred from the fundraising account to replace the funds used [5][6] Impact on Daily Operations - The use of own funds and bank acceptance bills is expected to enhance the efficiency of fund utilization without affecting the normal operation of fundraising projects or the company's daily business [6][7] Review Procedures - The board and supervisory committee have approved the proposal to use own funds and bank acceptance bills, which does not require shareholder approval [6][7] - The proposal aligns with regulatory requirements and does not alter the intended use of the raised funds [6][7]